bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but it is important to cut through the jargon and understand the business. Here is the breakdown in plain English.

1. What does this company actually do?

BioAffinity is a medical technology company focused on early lung cancer detection. Their main product is CyPath® Lung. This non-invasive test analyzes a patient’s phlegm to identify cancerous or precancerous cells.

The test uses automated analysis to help doctors evaluate spots on the lung. By providing a clearer assessment, the test helps patients avoid unnecessary, risky biopsies. The company is preparing for a 3,200-patient clinical trial, expected to open in the second quarter of 2025, to further validate the test’s effectiveness.

2. How do they make money?

The company is in the early stages of commercialization. They generated $9.4 million in revenue in 2024, up from $2.5 million in 2023. This growth was driven by expanding their laboratory services.

Are they growing? They are shifting from a research-focused model to a commercial one. To improve their financial health, management has launched a plan to save $4 million annually by cutting labor costs and phasing out lower-profit laboratory services to focus entirely on selling CyPath® Lung.

3. What is their financial situation?

This is the most important part for an investor: The company is burning cash.

As of December 31, 2024, they had an accumulated loss of $53.6 million and only $1.1 million in cash. Because expenses currently exceed revenue, the company relies on outside funding to operate.

The "Going Concern" Warning: Their auditors have flagged "substantial doubt" about the company’s ability to stay in business. Without new funding or a strategic partnership, the company may run out of money. Management noted that their cash was only expected to last through April 2025.

4. What are the main risks?

• Survival Risk: The need for cash creates a high risk of issuing more shares. This dilutes existing shareholders, meaning your ownership percentage in the company decreases.
• Regulatory Hurdles: CyPath® Lung is currently sold as a "Laboratory Developed Test." To reach a wider market and secure insurance reimbursement, the company needs FDA clearance. There is no guarantee they will receive this approval.
• Clinical Trial Uncertainty: The upcoming 3,200-patient trial is expensive and complex. Success depends on recruiting enough patients and meeting specific medical endpoints. Failure to meet these goals would likely hurt the company’s value significantly.
• Management Control: Investors are betting that management will spend limited capital wisely, but there is no guarantee that their current strategy will lead to profitability.

5. Who is running the company?

Maria Zannes is the President and CEO. She has a background in law and business and is the primary leader driving the company’s transition from a research-heavy organization to a commercial diagnostic provider.

6. Where will it trade?

You can find them on the Nasdaq under the ticker symbol BIAF. They also have tradeable warrants listed under BIAFW.

A quick word of advice: Small biotech stocks are inherently volatile. Prices can swing wildly based on news, trial results, or funding announcements. If you choose to invest, only use money you can afford to lose. Always check the latest SEC filings (specifically the 10-K and 10-Q reports) for the most recent financial updates before making a decision.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only and does not constitute financial advice.